

Lucie Peuvrel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477552/publications.pdf>

Version: 2024-02-01

57
papers

1,064
citations

304368

22
h-index

454577

30
g-index

61
all docs

61
docs citations

61
times ranked

1875
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of cetuximab in the treatment of squamous cell carcinoma. <i>Journal of Dermatological Treatment</i> , 2014, 25, 424-427.	1.1	54
2	Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. <i>Supportive Care in Cancer</i> , 2012, 20, 909-921.	1.0	45
3	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. <i>Oncologist</i> , 2012, 17, 555-568.	1.9	44
4	Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 890-897.	0.6	43
5	Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. <i>Journal of Neuro-Oncology</i> , 2014, 120, 147-154.	1.4	42
6	Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. <i>European Journal of Dermatology</i> , 2013, 23, 879-881.	0.3	40
7	Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1006-1009.	1.3	40
8	Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1468-1470.	0.3	37
9	Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 348-350.	1.2	36
10	Evaluation of Quality of Life after a Medical Corrective Make-Up Lesson in Patients with Various Dermatoses. <i>Dermatology</i> , 2012, 224, 374-380.	0.9	34
11	Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baseline. <i>Experimental Dermatology</i> , 2016, 25, 783-788.	1.4	34
12	Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. <i>Acta Dermato-Venereologica</i> , 2018, 98, 406-410.	0.6	31
13	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	1.7	31
14	Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 425-444.	3.3	30
15	Histopathological aspects of cutaneous erythematous papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. <i>International Journal of Dermatology</i> , 2017, 56, 527-533.	0.5	30
16	Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. <i>Supportive Care in Cancer</i> , 2012, 20, 1395-1404.	1.0	29
17	Profile of vemurafenib-induced severe skin toxicities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 250-257.	1.3	27
18	Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor. <i>Dermatology</i> , 2012, 224, 204-208.	0.9	26

#	ARTICLE	IF	CITATIONS
19	Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing) Tj ETQq1 1.0,784314,rgBT /Over	2.0	26
20	Early-Onset Vemurafenib-Induced DRESS Syndrome. <i>Dermatology</i> , 2016, 232, 126-128.	0.9	25
21	Melanoma and Rituximab: An Incidental Association?. <i>Dermatology</i> , 2013, 226, 274-278.	0.9	23
22	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	23
23	Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1711-1721.	0.9	22
24	Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive. <i>European Journal of Dermatology</i> , 2015, 25, 452-456.	0.3	19
25	Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. <i>Journal of Neuro-Oncology</i> , 2016, 126, 355-360.	1.4	19
26	Sudden Onset of an Aggressive Cutaneous Lymphoma in a Young Patient With Psoriasis: Role of Immunosuppressants. <i>Acta Dermato-Venereologica</i> , 2010, 90, 616-620.	0.6	18
27	Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 419-429.	1.3	18
28	<i>BRAF</i> mutations might be more common than supposed in vulvar melanomas. <i>Experimental Dermatology</i> , 2018, 27, 210-213.	1.4	17
29	Clinical, biological and histological characteristics of bullous pemphigoid associated with anti- <i>PD-1/PD-L1</i> therapy: A national retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e511-e514.	1.3	17
30	Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014, 131, 375-383.	0.4	16
31	Three new cases of bullous pemphigoid during anti- <i>PD-1</i> antibody therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e104-e106.	1.3	16
32	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. <i>European Journal of Dermatology</i> , 2019, 29, 315-321.	0.3	14
33	Vorinostat for Refractory or Relapsing Epidermotropic T-cell Lymphoma: A Retrospective Cohort Study of 15 Patients. <i>Acta Dermato-Venereologica</i> , 2015, 95, 72-77.	0.6	13
34	Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. <i>Supportive Care in Cancer</i> , 2016, 24, 1689-1695.	1.0	13
35	Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e39-e40.	1.3	13
36	Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 558-562.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Impact of a campaign to train general practitioners in screening for melanoma. <i>European Journal of Cancer Prevention</i> , 2009, 18, 225-229.	0.6	12
38	Systemic Rituximab in Multifocal Primary Cutaneous Follicle Centre Lymphoma. <i>Acta Dermato-Venereologica</i> , 2011, 91, 562-567.	0.6	12
39	Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. <i>Acta Dermato-Venereologica</i> , 2017, 97, 483-488.	0.6	7
40	Treatment of a multicentric Merkel cell carcinoma using imatinib. <i>European Journal of Dermatology</i> , 2011, 21, 1009-1010.	0.3	6
41	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. <i>Oncology Reports</i> , 2014, 32, 808-814.	1.2	6
42	5-fluorouracil chemowraps for the treatment of multiple actinic keratoses. <i>European Journal of Dermatology</i> , 2017, 27, 635-640.	0.3	6
43	Autoimmune thyroiditis and isotretinoin: real association or coincidence?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 125-126.	1.3	5
44	Tissue Biomarkers in Melanoma Patients Treated with TIL. <i>PLoS ONE</i> , 2012, 7, e48729.	1.1	4
45	Dramatic response of an inoperable Merkel cell carcinoma with imatinib. <i>JAAD Case Reports</i> , 2016, 2, 16-18.	0.4	4
46	Atypical cutaneous vasculitis under lapatinib. <i>European Journal of Dermatology</i> , 2013, 23, 540-541.	0.3	3
47	Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. <i>European Journal of Dermatology</i> , 2018, 28, 661-667.	0.3	3
48	Predictive value of Tâ€cell clone and <sc>CD</sc>13 antigen in parapsoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 518-520.	1.3	2
49	TOXICAN: a guide for grading dermatological adverse events of cancer treatments. <i>Supportive Care in Cancer</i> , 2018, 26, 2871-2877.	1.0	2
50	Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2018, 98, 530-531.	0.6	2
51	Exceptional Association of Syringotropic Mycosis Fungoides with Chronic Lymphocytic Leukaemia. <i>Acta Dermato-Venereologica</i> , 2016, 96, 263-264.	0.6	1
52	First case of trastuzumab emtansine-associated hemorrhagic telangiectasias treated with propranolol. <i>Dermatologic Therapy</i> , 2019, 32, e12756.	0.8	1
53	Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1311-1317.	1.3	0
54	Acneiform rash: an unusual presentation of epithelioid haemangioma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 470-472.	1.3	0

#	ARTICLE	IF	CITATIONS
55	BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity.. Journal of Clinical Oncology, 2014, 32, 9017-9017.	0.8	0
56	Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency.. Journal of Clinical Oncology, 2014, 32, 9069-9069.	0.8	0
57	Incidence and characteristics of melanoma brain metastases appearing during vemurafenib treatment.. Journal of Clinical Oncology, 2014, 32, 9042-9042.	0.8	0